SCHEMBL21044306

SCHEMBL21044306

COc1ccc(C(OC[C@H]2O[C@@H](n3cnc4c(NC(=O)c5ccccc5)ncnc43)C[C@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TYMP P19971 3/20 0.58
P2RY12 Q9H244 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824084 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL29674530 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL31556050 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL29674456 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL29674438 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL22984001 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL3824088 1.00 TYMP (0.58) TYMPP2RY12
SCHEMBL29720432 0.95 TYMP (0.63) TYMPP2RY12
SCHEMBL11040442 0.95 TYMP (0.63) TYMPP2RY12
SCHEMBL31093231 0.93 TYMP (0.49) TYMPP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250262298-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-21 US disclosed
EP-4242212-A2 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING Takeda Pharmaceutical Company Limited (JP) 2023-09-13 EP disclosed
US-20230159922-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2023-05-25 US disclosed
EP-4013428-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF Ionis Pharmaceuticals, Inc. (US) 2022-06-22 EP disclosed
US-20210309690-A1 OLIGONUCLEOTIDE SYNTHESIS ROCHE INNOVATION CT COPENHAGEN AS (DK) 2021-10-07 US disclosed
EP-3861118-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF Ionis Pharmaceuticals, Inc. (US) 2021-08-11 EP disclosed
WO-2021030763-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2021-02-18 WO disclosed
EP-3768685-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING Takeda Pharmaceutical Company Limited (JP) 2021-01-27 EP disclosed
US-20210015915-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-01-21 US disclosed
WO-2020072991-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2020-04-09 WO disclosed
WO-2019180683-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-09-26 WO disclosed
EP-3491002-A2 SYNTHESIS OF OLIGONUCLEOTIDES COMPRISING ACHIRAL 3'-S- OR 5'-S-PHOSPHOROTHIOLATE INTERNUCLEOSIDE LINKAGE Roche Innovation Center Copenhagen A/S (DK) 2019-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309690-A1 OLIGONUCLEOTIDE SYNTHESIS RNGTT, RTCB, TYMS TYMP 7/4885P2RY12 716/4885
US-20250262298-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING STING1, CGAS, TBK1 TYMP 962/4885P2RY12 242/4885
US-20210015915-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING STING1, CGAS, TBK1 TYMP 962/4885P2RY12 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.